Treatment of patients with progressive unresectable metastatic melanoma with a heterologous polyvalent melanoma whole cell vaccine-Reference-Cited by-同舟云学术

Treatment of patients with progressive unresectable metastatic melanoma with a heterologous polyvalent melanoma whole cell vaccine

Published:2003-05-30 Issue:4 Volume:106 Page:626-631
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Vilella Ramon¹,Benitez Daniel¹,Milà Jordi¹,Vilalta Antoni²,Rull Ramon³,Cuellar Francisco²,Conill Carles⁴,Vidal‐Sicart Sergi⁵,Costa Josep⁶,Yachi Eva²,Palou Josep²,Malvehy Josep²,Puig Susana²,Marti Rosa²,Mellado Begoña⁷,Castel Teresa²

Affiliation:

1. Department of Immunology, Hospital Clinic and IDIBAPS, Barcelona, Spain

2. Department of Dermatology, Hospital Clinic and IDIBAPS, Barcelona, Spain

3. Department of Surgery, Hospital Clinic and IDIBAPS, Barcelona, Spain

4. Department of Radiotherapy, Hospital Clinic and IDIBAPS, Barcelona, Spain

5. Department of Nuclear Medicine, Hospital Clinic and IDIBAPS, Barcelona, Spain

6. Department of Microbiology, Hospital Clinic and IDIBAPS, Barcelona, Spain

7. Department of Oncology, Hospital Clinic and IDIBAPS, Barcelona, Spain

Funder

Fondo de Investigaciones Sanitarias

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.11242

Reference28 articles.

1. Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma

2. Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma

3. Prognostic factors in 1,521 melanoma patients with distant metastasis;Barth A;J Am Coll Surg,1995

4. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa and interleukin‐2 for patients with metastatic melanoma;Bedikian A;J Clin Oncol,1998

5. Phase II pilot trial of concurrent biochemotherapy with cisplatin, vinbastine, temozolomide (CVT), interleukin‐2 (IL‐2) and interferon α‐2b (IFN) in patients with metastatic melanoma;Atkins M;Proc ASCO,1998

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HRK downregulation and augmented BCL-xL binding to BAK confer apoptotic protection to therapy-induced senescent melanoma cells.;2024-07-03

2. Cancer Vaccines in the Immunotherapy Era: Promise and Potential;Vaccines;2023-11-29

3. Harnessing the Immune System to Target Cancer Cells;Resistance to Targeted Anti-Cancer Therapeutics;2019

4. Methods for improving the immunogenicity and efficacy of cancer vaccines;Expert Opinion on Biological Therapy;2018-06-17

5. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette–Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma;Frontiers in Immunology;2018-03-02